GERIATRIC MEDICINE: AT THE LIMITS OF EVIDENCE-BASED PRACTICE*

1 Sudlow M R Thomson Thwaites B Prevalence of atrial fibrillation and eligibility for anticoagulation in the community. Lancet 1998; 352:1167-71.

2 Aronow WS C Ahn Gutstein H. Prevalence of atrial fibrillation and association of atrial fibrillation with prior and new thromboembolic stroke in older patients. J Am Geriatr Soc 1996; 44:521-3.

3 Danias PG TA Caulfield Weigner MJ Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm. J Am Coll Cardiol 1998; 32:551-2.

4 Van Gelder IC HJ Crijns Van Gilst WH Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991; 68:41-6.

5 Roy D M Talajic Dorian P Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of atrial fibrillation investigators. N Engl J Med 2000; 342:913-20.

6 Oral H JJ Souza Michaud GF Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med 1999; 340:1849-54.

7 Gosselink AT HJ Crijns van den Berg MP Functional capacity before and after cardioversion of atrial fibrillation: a controlled study. Br Heart J 1994; 72:161-6.

8 Weigner MJ TA Caulfield Danias PG Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med 1997;126:615-20.

9 Palareti I J Hirch Legnani C Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study. Arch Intern Med 2000; 160:470-8.

10 Wilson PW RD Abbott Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1998; 8:737-41.

11 Smith GD MJ Shipley Marmot MG Patient cholesterol concentration and mortality. The Whitehall Study. JAMA 1992; 267:70-6.

12 Clarke R M Shipley Lewington S Underestimation of risk associations due to regression dilution in long-term followup of prospective studies. Am J Epidemiol 1999; 150:341-53.

13 Elam B. Increased mortality in older persons with hypocholesterolemia: cause or effect. J Am Geriatr Soc 1995; 43:312-3.

14 Chyou PH Eaker ED. Serum cholesterol concentrations and all-cause mortality in older people. Age Ageing 2000; 29: 69-74.

15The Scandinavian Simvastatin Survival Study Investigators. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-9.

16 Sacks FM MA Pfeffer Moye LA The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med; 335:1001-9.

17The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol level. N Engl J Med 1998; 339:1349-57.

18Heart Protection Study Investigators. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary disease and death: early safety and efficacy experience. Eur Heart J 1999; 20P:725-41.

19 Shepherd J Blauw GJ Murphy MB The design of a prospective study of pravastatin in the elderly at risk (PROSPER). Am J Cardiol 1999; 84:1192-7.

20 Cummings SR JL Kelsey Nevitt MC Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev 1985; 7:178-208.

21 Chapuy MC ME Arlot Delmas PD Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994; 308:1081-2.

22 Heikinheimo RJ MV Haavisto Harju EJ Serum vitamin D level after annual intramuscular injection of ergocalciferol. Calcif Tissue Int 1991; 49(Suppl):S87.

23 Dawson-Hughes BB SS Harris Krall EA Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337:670-6.

24 Lips P WC Graafmans Ooms ME Vitamin D supplementation and fracture incidence in elderly persons. A randomised, placebo-controlled clinical trial. Ann Intern Med 1996; 124:400-6.

25 Parker MJ LD Gillespie Gillespie WJ. Hip protectors for preventing hip fractures in the elderly. Cochrane Database of Systematic Reviews. Issue 1; 2000.

26 Erkinjuntti T T Ostbye Steenhuis R The effect of different diagnostic criteria on the prevalence of dementia. N Engl J Med 1997; 337:1667-74.

27 Staessen JA R Fagard Thijs L Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350:757-64.

28 Dunlop MG. Colorectal cancer. BMJ 1997; 314:1882-5.

29 Brown JS D Eraut Trask C Age and the treatment of lung cancer. Thorax 1996; 51:564-8.

30De Perrot M, Licker M, Reymond MA Influence of age on operative mortality and long-term survival after lung resection for bronchogenic carcinoma. Eur Respir J 1999; 14:419-22.

31 Souquet PJ CH Lombard-Bohas Freyer G Chemotherapy in elderly patients with bronchogenic carcinoma. Rev Mal Resp 1996; 13:327–33.

32 Gotzsche PC Olsen O. Is screening for breast cancer with mammography justifiable? Lancet 2000; 355:129-34.

33The National Institute of Neurological Disorders and Stroke rt-PA Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333:1581-7.

34 Hacke W M Kaste Fieschi C Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study. JAMA 1995; 274:1017-25.

35 Hacke W M Kaste Fieschi C Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998; 352:1245-51.

36 Ford G Freemantle N. ECASS II: intravenous alteplase in acute ischaemic stroke. European Co-operative Acute Stroke Study-II. Lancet 1999; 353:65.

37 Wardlaw JM G Del Zoppo Yamaguchi T. Thrombolysis for acute ischaemic stroke. Cochrane Database of Systematic Reviews. Issue 1; 2000.

38 Hankey GJ Treatment Warlow CP. prevention secondary of stroke: evidence, costs and effects on individuals and populations. Lancet 1999; 354:1457-14.